Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma

European Urology

Volumn 66, Issue 5, 2014, Pages 929-935

  Parker, Alexander S ^a   Eckel Passow, Jeanette E ^b   Serie, Daniel ^a   Hilton, Tracy ^a   Parasramka, Mansi ^a   Joseph, Richard W ^a   Wu, Kevin J ^a   Cheville, John C ^b   Leibovich, Bradley C ^c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c DEPARTMENT OF UROLOGY   (United States)

Author keywords

Biologic; Carcinoma, renal cell; Kidney neoplasms; Survival; Tumor biomarkers

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; TUMOR MARKER; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR NECROSIS; UNITED STATES; VERY ELDERLY; ADVERSE EFFECTS; BIOPSY; CARCINOMA, RENAL CELL; CLINICAL TRIAL; ENZYMOLOGY; FLORIDA; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; MINNESOTA; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NECROSIS; OBSERVER VARIATION; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REGISTER; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; TERTIARY CARE CENTER; TIME FACTOR; TREATMENT OUTCOME; TUMOR VOLUME; UPREGULATION; VALIDATION STUDY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, RENAL CELL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; FLORIDA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; NECROSIS; NEOPLASM GRADING; NEOPLASM STAGING; NEPHRECTOMY; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; UP-REGULATION; YOUNG ADULT;

EID: 84907578775     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.12.017     Document Type: Article

References (19)

1. M. Sun, R. Thuret, and F. Abdollah Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis Eur Urol 59 2011 135 141
2. E. Cho, H.O. Adami, and P. Lindblad Epidemiology of renal cell cancer Hematol Oncol Clin North Am 25 2011 651 665
3. W.H. Chow, S.S. Devesa, J.L. Warren, and J.F. Fraumeni Jr. Rising incidence of renal cell cancer in the United States JAMA 281 1999 1628 1631
4. J.A. Leslie, T. Prihoda, and I.M. Thompson Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes Urol Oncol 21 2003 39 44
5. J.E. Deweese, and N. Osheroff The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing Nucleic Acids Res 37 2009 738 748
6. J.L. Nitiss DNA topoisomerase II and its growing repertoire of biological functions Nat Rev Cancer 9 2009 327 337
7. R.P. Bakshi, S. Galande, and K. Muniyappa Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase Crit Rev Biochem Mol Biol 36 2001 1 37
8. P.L. Depowski, S.I. Rosenthal, T.P. Brien, S. Stylos, R.L. Johnson, and J.S. Ross Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables Mod Pathol 13 2000 542 547
9. Erguden HÇ, D. Koksal, and F. Demirag The association of topoisomerase 2α expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients J Thorac Dis 4 2012 352 357
10. M.F. de Resende, S. Vieira, and L.T. Chinen Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer J Transl Med 11 2013 36
11. J.M. Fortune, and N. Osheroff Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice Prog Nucleic Acid Res Mol Biol 64 2000 221 253
12. A.S. Parker, J.C. Cheville, C.M. Lohse, T. Igel, B.C. Leibovich, and M.L. Blute Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma Urology 65 2005 1090 1095
13. F.E. Harrell, K.L. Lee, and D.B. Mark Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
14. I. Frank, M.L. Blute, J.C. Cheville, C.M. Lohse, A.L. Weaver, and H. Zincke An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score J Urol 168 2002 2395 2400
15. Y. Fujii, K. Saito, and Y. Iimura External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma J Urol 180 2008 1290 1295
16. R. Zigeuner, G. Hutterer, and T. Chromecki External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology Eur Urol 57 2010 102 111
17. M.B. Atkins, D.E. Avigan, and R.M. Bukowski Innovations and challenges in renal cancer: consensus statement from the first international conference Clin Can Res 10 2004 6277S-81S
18. J.S. Lam, O. Shvarts, J.T. Leppert, R.A. Figlin, and A.S. Belldegrun Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy J Urol 173 2005 1853 1862
19. A.S. Parker, B.C. Leibovich, and C.M. Lohse Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma Cancer 115 2009 2092 2103